Skip to content
The Policy VaultThe Policy Vault

Ojjaara (momelotinib) — United Healthcare

intermediate or high-risk myelofibrosis (MF)

Initial criteria

  • Patient is less than 19 years of age

Reauthorization criteria

  • Continuation per age-based provision

Approval duration

12 months